14.32
-0.42 (-2.85%)
| Penutupan Terdahulu | 14.74 |
| Buka | 14.50 |
| Jumlah Dagangan | 960,313 |
| Purata Dagangan (3B) | 1,014,176 |
| Modal Pasaran | 1,904,144,384 |
| Harga / Pendapatan (P/E TTM) | 6.92 |
| Harga / Pendapatan (P/E Ke hadapan) | 18.59 |
| Harga / Jualan (P/S) | 7.55 |
| Harga / Buku (P/B) | 5.11 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| Margin Keuntungan | 16.11% |
| Margin Operasi (TTM) | 37.43% |
| EPS Cair (TTM) | 0.270 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.25% |
| Nisbah Semasa (MRQ) | 5.93 |
| Aliran Tunai Operasi (OCF TTM) | 64.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 47.49 M |
| Pulangan Atas Aset (ROA TTM) | 5.20% |
| Pulangan Atas Ekuiti (ROE TTM) | 11.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Aurinia Pharmaceuticals Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.07% |
| % Dimiliki oleh Institusi | 47.53% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nea Management Company, Llc | 31 Dec 2025 | 3,969,834 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DONLEY MATTHEW MAXWELL | 14.17 | 14.21 | 17,399 | 244,913 |
| GREENLEAF PETER | 14.17 | 14.21 | 95,513 | 1,349,384 |
| KEENAN GREG | 14.17 | - | 40,586 | 575,104 |
| MILLER JOSEPH M | 14.17 | 14.21 | 19,718 | 277,904 |
| ROBERTSON STEPHEN P. | 14.17 | 14.21 | 22,565 | 318,285 |
| TANG KEVIN | 14.18 | - | 900,000 | 12,757,290 |
| Jumlah Keseluruhan Kuantiti Bersih | 1,095,781 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 15,522,879 | |||
| Purata Pembelian Keseluruhan ($) | 14.17 | |||
| Purata Jualan Keseluruhan ($) | 14.21 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TANG KEVIN | Pengarah | 03 Mar 2026 | Beli (+) | 184,208 | 14.15 | 2,606,543 |
| GREENLEAF PETER | Pegawai | 02 Mar 2026 | Dibuang (-) | 100,890 | 14.21 | 1,433,647 |
| MILLER JOSEPH M | Pegawai | 02 Mar 2026 | Dibuang (-) | 37,511 | 14.21 | 533,031 |
| ROBERTSON STEPHEN P. | Pegawai | 02 Mar 2026 | Dibuang (-) | 36,525 | 14.21 | 519,020 |
| DONLEY MATTHEW MAXWELL | Pegawai | 02 Mar 2026 | Dibuang (-) | 40,761 | 14.21 | 579,214 |
| TANG KEVIN | Pengarah | 02 Mar 2026 | Beli (+) | 199,353 | 14.21 | 2,832,806 |
| GREENLEAF PETER | Pegawai | 27 Feb 2026 | Diperolehi (+) | 196,403 | 14.17 | 2,783,031 |
| MILLER JOSEPH M | Pegawai | 27 Feb 2026 | Diperolehi (+) | 57,229 | 14.17 | 810,935 |
| KEENAN GREG | Pegawai | 27 Feb 2026 | Diperolehi (+) | 40,586 | 14.17 | 575,104 |
| ROBERTSON STEPHEN P. | Pegawai | 27 Feb 2026 | Diperolehi (+) | 59,090 | 14.17 | 837,305 |
| DONLEY MATTHEW MAXWELL | Pegawai | 27 Feb 2026 | Diperolehi (+) | 58,160 | 14.17 | 824,127 |
| TANG KEVIN | Pengarah | 27 Feb 2026 | Beli (+) | 516,439 | 14.17 | 7,317,941 |
| Papar semua | ||||||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |